

### Data Sharing Statement

|                     |   |   |
|---------------------|---|---|
| <b>Article Info</b> | <a href="https://dx.doi.org/10.21037/jtd-23-1399">https://dx.doi.org/10.21037/jtd-23-1399</a>   |   |
| <b>Item</b>         | <b>Question</b>   | <b>Authors' Response<br/>(place "-" if not applicable)</b>  |
| 1                   | Would you like to share data collected for your study to others?  | No.   |
| 2                   | If not, would you like to share the reason for your decision?   | -   |
| 3                   | What data in particular will be shared?   | -   |
| 4                   | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Study protocol, statistical analysis plan, clinical study report, analytic code.  |
| 5                   | When will data availability begin?  | Immediately following publication.  |
| 6                   | When will data availability end?  | Two years within the publication date, since the technique or survival data may be updated over time.                                       |
| 7                   | To whom will you share the data?  | Medical oncologists who are interested in studies of anti-PD-1 in patients with advanced EGFR-TKI-resistant lung cancer.                    |
| 8                   | For what type of analysis or purpose?   | For analysis to evaluate the efficacy and safety of anti-PD-1 in patients with advanced experienced EGFR-TKI-resistant lung adenocarcinoma. |
| 9                   | How or where can the data/documents be obtained?  | Emails could be sent to the address below to obtain the shared documents: <a href="mailto:duyingying@126.com">duyingying@126.com</a> .      |
| 10                  | Any other restrictions?   | No.   |